Radiotherapy plus camrelizumab affects peripheral CD8 T-cell differentiation subsets expressing PD-1, TIGIT, and CTLA-4 in esophageal squamous cell carcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of leukocyte biology"
DOI: 10.1093/jleuko/qiac018
Abstract: Our previous phase Ib trial (NCT03222440) showed that radiotherapy plus the anti-PD-1 antibody camrelizumab is a safe and feasible first-line therapy for locally advanced esophageal squamous cell carcinoma. In this study, we divided peripheral CD8… read more here.
Keywords: cell; cell carcinoma; squamous cell; plus camrelizumab ... See more keywords